How We Helped A Sponsor Go From Safety Assessment To Proof-Of-Concept In 22 Months

What if the biggest obstacle to faster drug development isn’t the studies themselves, but the time lost between them? For sponsors balancing competitive pressure, funding milestones, and the need for clinically meaningful data, those operational gaps can add months to an early-phase program.
A biotech developing an incretin-based injectable tackled this challenge by integrating nonclinical, bioanalytical, regulatory, and clinical activities from the beginning. Instead of moving sequentially from one stage to the next, analytical methods, toxicology studies, protocols, and regulatory preparations advanced in parallel. Emerging findings could then inform first-in-human dosing, submission planning, and later clinical decisions as soon as they became available.
This coordinated approach helped move the program from initial safety assessment to proof-of-concept topline results in approximately 22 months, while preserving scientific and regulatory rigor. See how reducing development whitespace can accelerate critical milestones and bring meaningful clinical data into view sooner.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.